赛默飞世尔股价异动：业绩超预期与保守指引并存

Financial Performance - The company reported a 7.2% year-over-year revenue growth for Q4 2025 and a 7.7% increase in adjusted earnings per share (EPS), both exceeding market expectations [2] - However, the company issued a profit guidance for 2026 indicating that annual profits may fall below Wall Street expectations, citing ongoing pressure from cuts in U.S. academic research funding [2] Company Status - The company announced plans to gradually close its Franklin, Massachusetts facility and lay off 103 employees, with completion expected by the end of 2026. This follows the closure of the Asheville, North Carolina plant, indicating a strategy to optimize global operational efficiency [3] - Management acknowledged the dual challenges of cost pressures and weak demand [3] Industry Policy and Environment - Demand from pharmaceutical clients showed a significant rebound in Q4 2025, but equipment demand from U.S. government and academic clients remained weak due to budget constraints [4] - Policies from the Trump administration that reduced research funding may continue to impact some of the company's core customers, raising investor concerns about short-term growth momentum [4] Stock Performance - From January 13 to February 11, 2026, the company's stock price fell by 14.29%, with a single-day drop of 2.28% on February 11, closing at $527.49. This decline occurred despite relatively stable movements in the broader U.S. stock market, indicating that specific company factors influenced the stock's volatility [5] Institutional Perspectives - While several Wall Street firms maintain a buy rating, some investors are more focused on the weak short-term earnings guidance and operational contraction risks [6] - There are opinions suggesting that the company's long-term competitiveness remains solid due to strategic acquisitions and a recovery in biopharmaceutical demand [6]